Botox is a commercial form of botulinum toxin (a neurotoxin which inhibits the release of acetyl choline from the presynaptic membrane of the neuromuscular junction, leading to paresis or paralysis).

**Pre-Authorization Criteria:**
VCHCP will approve Botox for: blepharospasm, cervical dystonia, axillary hyperhydrosis, sialorrhea, spasticity due to stroke or cerebral palsy, upper extremity dystonias, hyperactive Bladder; headache prophylaxis in adults with chronic migraines (at least 15 days of headache per month and at least 8 days of migraine) that have not responded to at least 3 prior pharmacologic prophylaxis therapies and whose condition is appropriately managed for medication overuse. (See Milliman Care Guidelines for additional details.)

**Adult Dosing:** varies, see product information

**PRECAUTIONS:** should be administered by a practitioner specially trained in its use; distant spread of toxin beyond site of injection [U.S. Boxed Warning]; loss of efficacy due to antibody formation after prolonged use; unwanted reactions at injection sites (bleeding; excessive paresis); dry cornea/corneal abrasion from reduced blink reflexes

**DRUG INTERACTIONS:** neuromuscular blocking agents; anticholinergic agents; aminoglycosides

**Note:** Onabotulinum (Botox) and abobotulinumtoxin (Dysport) have unique dosing, as spelled out in each agent’s prescribing information. It is important that physicians be familiar with the respective dosing guidelines for each agent and be prepared to make appropriate treatment decisions in any clinical setting.

**REFERENCES**


Revision History:
Date Reviewed/No Updates: 01.28.14 by C. Sanders MD
Date Approved by P&T Committee: 01.28.14
Date Reviewed/No Updates: 01.13.15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15
Date Reviewed/Updated: 02.05.15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16